The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...